Journal ArticleDOI
Whole blood coagulation assays ROTEM and T-TAS to monitor dabigatran treatment.
V. Taune,Håkan Wallén,Anna Ågren,Gunilla Gryfelt,Carolina Sjövik,Anna M. Wintler,Rickard E. Malmström,Agneta Wikman,Mika Skeppholm,Mika Skeppholm +9 more
Reads0
Chats0
TLDR
ROTEM Ex-tem and Fib-tem CT shows a strong correlation with dabigatran concentrations in real-life AF-patients, and results are obtained within minutes, which could make ROTEM useful in acute situations.About:
This article is published in Thrombosis Research.The article was published on 2017-05-01. It has received 28 citations till now. The article focuses on the topics: Dabigatran & Thromboelastometry.read more
Citations
More filters
Journal ArticleDOI
Reversal agents for non-vitamin K antagonist oral anticoagulants
TL;DR: The approved indications for the NOACs are summarized, how to measure their anticoagulant effects, and the mechanism of action of the reversal strategies are described, to assess the preclinical and clinical data supporting their use, and guidance on potential indications for reversal is provided.
Journal ArticleDOI
Impact of four direct oral anticoagulants on rotational thromboelastometry (ROTEM)
TL;DR: The aim of this study was to determine the impact of four direct oral anticoagulants (DOACs) on 3 commonly used ROTEM tests.
Journal ArticleDOI
Role of Thromboelastography and Rotational Thromboelastometry in the Management of Cardiovascular Diseases
Barbora Korpallová,Matej Samoš,Tomáš Bolek,Ingrid Škorňová,František Kovář,Peter Kubisz,Jan Stasko,Marián Mokáň +7 more
TL;DR: There is perspective for more frequent use of these assays in the assessment of platelet response to antiplatelet therapy and in the Assessment of coagulation in patients on long-term dabigatran therapy.
Journal ArticleDOI
Emergency care of patients receiving non-vitamin K antagonist oral anticoagulants.
John W. Eikelboom,S. Kozek-Langenecker,Aristomenis K. Exadaktylos,Angelika Batorova,Z. Boda,F. Christory,Ivan Gornik,Ivan Gornik,G. Kėkštas,A. Kher,R. Komadina,O. Koval,G. Mitic,T. Novikova,E. Pazvanska,S. Ratobilska,J. Sütt,A. Winder,D. Zateyshchikov +18 more
TL;DR: Recent advances in the development of targeted reversal agents are expected to help streamline the management of NOAC‐treated patients in whom rapid reversal of anticoagulation is required.
Journal ArticleDOI
Comprehensive characteristics of the anticoagulant activity of dabigatran in relation to its plasma concentration
Willemijn J. Comuth,Linda Ø Henriksen,Daan van de Kerkhof,Steen Elkjær Husted,Steen Dalby Kristensen,Steen Dalby Kristensen,Moniek P.M. de Maat,Anna-Marie Bloch Münster +7 more
TL;DR: Extem and FIBTEM CT, ECA and LD-dTT are suitable for measuring the effect of dabigatran in treated patients and results from spiked plasma samples are similar to those of patient samples, with the exception of few ROTEM® parameters.
References
More filters
Journal ArticleDOI
Dabigatran versus warfarin in patients with atrial fibrillation
Stuart J. Connolly,Michael D. Ezekowitz,John W. Eikelboom,Jonas Oldgren,Amit Parekh,Janice Pogue,Paul A. Reilly,Ellison Themeles,Jeanne Varrone,Susan Wang,Marco Alings,Denis Xavier,Jun Zhu,Rafael Diaz,Basil S. Lewis,Harald Darius,Hans-Christoph Diener,Campbell D. Joyner,Lars Wallentin +18 more
TL;DR: In patients with atrial fibrillation, dabigatran given at a dose of 110 mg was associated with rates of stroke and systemic embolism that were similar to those associated with warfarin, as well as lower rates of major hemorrhage.
Journal ArticleDOI
Dabigatran versus warfarin in the treatment of acute venous thromboembolism
Sam Schulman,Clive Kearon,Ajay K. Kakkar,Patrick Mismetti,Sebastian Schellong,Henry Eriksson,David Baanstra,Janet Schnee,Samuel Z. Goldhaber,S. Schul +9 more
TL;DR: For the treatment of acute venous thromboembolism, a fixed dose of dabigatran is as effective as warfarin, has a safety profile that is similar to that of warfar in, and does not require laboratory monitoring.
Journal Article
Dabigatran versus warfarin in patients with atrial fibrillation.
TL;DR: Dabigatran appeared to be more efficacious in patients who weighed less and in patients with impaired renal function (in whom the drug ac cumulates), pointing to significant interpatient variability in response.
Journal ArticleDOI
Idarucizumab for Dabigatran Reversal
Charles V. Pollack,Paul A. Reilly,John W. Eikelboom,Stephan Glund,Peter Verhamme,Richard A. Bernstein,Robert Dubiel,Menno V. Huisman,Elaine M. Hylek,Pieter W. Kamphuisen,Jörg Kreuzer,Jerrold H. Levy,Frank W. Sellke,Joachim Stangier,Thorsten Steiner,Bushi Wang,Chak Wah Kam,Jeffrey I. Weitz +17 more
TL;DR: Idarucizumab completely reversed the anticoagulant effect of dabigatran within minutes and normalized the test results in 88 to 98% of the patients, an effect that was evident within minutes.
Journal ArticleDOI
Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin
TL;DR: Observations suggest that PAR1 and PAR4 account for most, if not all, thrombin signaling in platelets and that antagonists that block these receptors might be useful antithrombotic agents.